Effectiveness and Complications of Anthracycline and Taxane in the Therapy of Breast Cancer: A Meta-analysis

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Pathology and Oncology Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12253-013-9681-6PMID 23980023
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjuvant docetaxel for high-risk, node-negative breast cancer.

  2010cited by this paper
• Epirubicin Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil versus Paclitaxel Followed by Epirubicin and Vinorelbine in Patients with High-Risk Operable Breast Cancer

  2010cited by this paper
• Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.

  2010cited by this paper
• Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

  2009cited by this paper
• Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

  2009cited by this paper
• FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)

  2009cited by this paper
• Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.

  2008cited by this paper
• Topoisomerase levels determine chemotherapy response in vitro and in vivo

  2008cited by this paper
• Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

  2008cited by this paper
• Treatment-experienced breast cancer.

  2008cited by this paper
• Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.

  2008cited by this paper
• Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

  2008cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• Benefit of taxanes as adjuvant chemotherapy for early breast cancer

  2006cited by this paper
• Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.

  2006cited by this paper
• Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

  2006cited by this paper
• Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

  2006cited by this paper
• Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

  2006cited by this paper
• Preoperative (neoadjuvant) systemic treatment of breast cancer.

  2005cited by this paper
• Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.

  2005cited by this paper
• Taxanes with anthracyclines as first‐line chemotherapy for metastatic breast carcinoma

  2005cited by this paper
• Prospective identification of tumorigenic breast cancer cells

  2003cited by this paper
• Comparative studies on biological activity of certain microtubule-interacting taxanes.

  2002cited by this paper
• Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

  2000cited by this paper
• The standard of reporting of health-related quality of life in clinical cancer trials.

  2000cited by this paper
• Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel

  1996cited by this paper
• Cancer statistics

  1989cited by this paper

• How Asian Breast Cancer Patients Experience Unequal Incidence of Chemotherapy Side Effects: A Look at Ethnic Disparities in Febrile Neutropenia Rates

  2023cites this paper
• The role and application of small extracellular vesicles in breast cancer

  2022cites this paper
• Grading Evaluation of Cardiotoxicity in Patients with Breast Cancer Treated with Adjuvant Paclitaxel Anthracycline/Cyclophosphamide Chemotherapy: A Meta-Analysis

  2022cites this paper
• Cardiotoxicity of chemotherapy and targeted agents.

  2021cites this paper
• Anticancer bioactive peptide combined with docetaxel and its mechanism in the treatment of breast cancer

  2020cites this paper
• Tumor‐derived exosomes: Potential biomarker or therapeutic target in breast cancer?

  2018cites this paper
• Tumor-derived exosomes : potential biomarker or therapeutic target in breast cancer ? † Running title : exosomes in breast cancer

  2017cites this paper
• CHEMOTHERAPY-INDUCED CARDIOTOXICITY IN ONCOLOGY DRUGS INVOLVED AND CLINICAL ASSESSMENT

  2016cites this paper
• Exosomes and breast cancer: a comprehensive review of novel therapeutic strategies from diagnosis to treatment

  2016cites this paper
• Extracellular vesicles in breast cancer drug resistance and their clinical application

  2016cites this paper
• Cardiotoxicity of anthracycline therapy: current perspectives

  2016cites this paper
• Economic burden of patients with inoperable advanced breast cancer receiving early or late capecitabine or trastuzumab as second-line treatment: A population-based study

  2015cites this paper
• Economic burden of patients with inoperable advanced breast cancer receiving early or late capecitabine or trastuzumab as second-line treatment : A population-based study

  2015cites this paper